Edgar Snyder & Associates®
A Law Firm Representing Injured People
1-866-943-3427
Call Us Toll Free 24/7
Published on Feb 23, 2007 by Edgar Snyder

Stronger Warning for Asthma Drug Xolair

Asthma Drug Xolair

If you, or someone you care about, take Xolair it may cause shortness of breath instead of relieving your asthma symptoms. Because of continued adverse side effects, the Food and Drug Administration (FDA) has proposed that the manufacturer, Genetech, Inc., modify the package of Xolair with a boxed warning.

Xolair is specifically designed to aid allergy sufferers who have not experienced adequate relief from asthma using more traditional steroid-based medications. However, Xolair has been linked to cases of anaphylaxis in approximately one out of every 1,000 users of the product. Anaphylaxis causes shortness of breath, tightening in the chest, dizziness, fainting, hives, and itching. Any dose of Xolair could lead to anaphylaxis in patients, even if the first dose of the drug caused no adverse reaction. Signs of anaphylaxis in users may not surface until up to 24 hours after using Xolair.

Free Case Review
First Name
Last Name
ZIP
Phone
Email
Briefly describe your injuries
Please note: All of our lawyers are licensed to practice in the state of Pennsylvania. We also have lawyers licensed to practice in Ohio and West Virginia, and we associate with experienced attorneys in other states. In addition, all drug-related litigation involves co-counsel.

Source: "FDA Proposes to Strengthen Label Warning for Xolair." FDA Press Release. February 21, 2007.
Think you have a case?
Think you have a case?
Free Case Review
First Name
Last Name
ZIP
Phone
Email
Briefly describe your injuries

Recent News

Sep 28, 2016
Pittsburgh Police Beefing Up DUI Patrols in 2017
Sep 26, 2016
Gear Up, Cool Down, and Stay Safe While Riding This Fall
Sep 16, 2016
Fall and Winter Car Kit
Sep 16, 2016
A New Law May Be Coming for Drivers
Sep 16, 2016
Smartphone Apps for Drivers
Tweet